Download Files:
Products Details
Product Description
– Brigatinib-13C6 is the 13C-labeled Brigatinib. Brigatinib (AP-26113) is a highly potent and selective ALK inhibitor, with an IC50 of 0.6 nM[1].
Web ID
– HY-12857S
Shipping
– Room temperature
Molecular Formula
– C23 13C6H39ClN7O2P
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Zhang S, et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016 Nov 15;22(22):5527-5538|[3]Huang WS, et al. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem. 2016 May 26;59(10):4948-64.|[4]Siaw JT, et al. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016 May 17;7(20):29011-22
Molecular Weight
– 590.05
SMILES
– CN1CCN(CC1)C2CCN(CC2)C3=CC=C(C(OC)=C3)NC4=NC=C(C(N[13C]5=[13CH][13CH]=[13CH][13CH]=[13C]5P(C)(C)=O)=N4)Cl
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Anaplastic lymphoma kinase (ALK);Isotope-Labeled Compounds
Pathway
– Others;Protein Tyrosine Kinase/RTK
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
